Valion Bio stockholders approve reverse split authority and equity plan amendment
At a virtual special meeting on November 12, 2026, Valion Bio stockholders approved all three proposals, including authority for the board to effect a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-12 within 12 months, without further stockholder approval. Stockholders also approved an amendment increasing the 2021 Equity Incentive Plan share reserve by 272,000 shares; the filing states that no other plan term or provision changed.
Key takeaways
Stockholders approved reverse stock split authority, but the filing announces authorization rather than an executed split or a selected ratio.
The board has 12 months from approval to determine a ratio between not less than 1-for-2 and not greater than 1-for-12 without further stockholder approval.
The 2021 Equity Incentive Plan share reserve was increased by 272,000 shares, effective upon approval, with no other plan term or provision changed.
The reverse stock split proposal received 681,523 votes for and 444,153 against, with 9 abstentions and no broker non-votes.
Stockholders authorized the board to adjourn the meeting to another place or later date to solicit additional proxies if necessary or appropriate.
The Form 8-K reported meeting voting results and disclosed no financial results or guidance.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow VBIO in real time
Get material earnings, filing, IR, and earnings-call alerts by email.